For example, in mucoepidermoid carcinoma, the discovery of PCP4/PEP19 and HER2 as novel prognostic markers is conducive to solving the problem of poor prognosis of cancer and can also be used in molecular-targeted therapies (31). Here, ERBB2 is linked to mucoepidermoid carcinoma.